Interstitial cystitis (IC) is a prolonged condition that causes bladder pressure, pain, and, in some cases, pelvic pain. The symptoms of interstitial cystitis may cause an impact on one’s social life, physical activity, sleep, and even on the ability to work. The disease tends to effect women more than the men. Common symptoms of interstitial cystitis include bladder pain and pressure, frequent urination, pain in vagina or vulva in case of women, and pain in scrotum or testicles in case of men. It is difficult to diagnose, therefore even though treatments can improve one's quality of life, there is no optimal cure.
The global interstitial cystitis drugs market is estimated to be US$ 206.6 Million in 2021 and is expected to reach US$ 323.4 million by 2028 to grow at a CAGR of 6.6% during the forecast period (2021 –2028).
The increasing number of product launches and drug approvals are expected to drive the market growth over the forecast period.
Key players are focusing on product launches and drug approval by regulatory authorities, which are expected to propel the market growth over the forecast period. For instance, in December 2019, the U.S. Food and Drugs Administration (FDA) issued a draft guidance outlining suggestions for the clinical development of new drugs to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS). This ultimately encourages sponsors of biopharmaceutical companies to manufacture and market more drugs related to interstitial cystitis or bladder pain syndrome.
Figure 1. Global Interstitial Cystitis Drugs Market Value (US$ Mn), and Y-o-Y Growth (%), 2017-2028
Interstitial Cystitis Drugs Market – Regional Analysis
North America region is expected to dominate with the largest market share in the global interstitial cystitis drugs market, owing to the increasing cases of interstitial cystitis in the region and the rise in research funding & advances in the diagnostic imaging of interstitial cystitis. For instance, the prevalent population of interstitial cystitis in the U.S. was reported to be 5,894,905 in 2018, which is expected to increase in the forecast period.
|Base Year:||2020||Market Size in 2021:||US$ 206.6 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||6.6%||2028 Value Projection:||US$ 323.4 Mn|
Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
|Restraints & Challenges:||
Global Interstitial Cystitis Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported in the U.S. as of July 14, 2021 are approximately 187,519,798 with around 4,049,372 deaths. The coronavirus or COVID-19 outbreak that started from Wuhan, China, and has spread across continents, affecting various industries globally. Continuous pain symptoms due to IC are also known to produce psychological disorders, such as anxiety and depression. Moreover, the spread of COVID-19 pandemic added to the distress of IC patients by causing psychological symptoms such as fear, sadness, boredom, frustration, and anger. A multidisciplinary approach offers a personalized treatment for IC patients by providing a web-mediated counseling intervention for patients and their caregivers. This can favor a relationship-based process of change aimed at an improvement in quality of life.
Figure 2. Global Interstitial Cystitis Drugs Market Share (%), By Drug 2021
Global Interstitial Cystitis Drugs Market: Restraint
The lack of approved drugs, side-effects due to available medications, low diagnosis rate of interstitial cystitis, and the high treatment cost are expected to restrain the market during the forecast period. In April 2020, the Food and Drug Administration (FDA) Trusted Source requested that all forms of prescription and over-the-counter (OTC) Ranitidine (Zantac) drugs should be removed from the U.S. market. This recommendation was made due to unacceptable levels of NDMA (a probable carcinogen (or cancer-causing chemical)) in some ranitidine drugs, which could negatively affect patients suffering from IC.
Major players operating in the global interstitial cystitis drugs market include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Interstitial Cystitis (IC) also called as painful bladder syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder expands until it is full and then gives signal to the brain that it is time to urinate, communicating through pelvic nerves. With IC, these signals get mixed up and then patient feels the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can has a long-lasting impact on the quality of life. Although there is no cure, medications, and other therapies may offer some relief.
There are two types of IC such as non-ulcerative IC, which is found in 90% of the population suffering from IC. It is characterized by pinpoint hemorrhages called glomerulations. Another type of IC is Ulcerative IC, which comprises of about 5-10% of the patient population. It is mainly characterized by Hunner’s ulcers and the patches that bleed on bladder walls. Hunner’s ulcers, also called “Hunner’s lesions” or “Hunner’s patches”, are a sub type of IC and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the “classic” form of IC, and it affects only about 5 to 10 percent of patients suffering from IC.
The high prevalence of interstitial cystitis is driving the global interstitial cystitis drugs market. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. According to Patnaik et al., 2017, prevalence estimates suggest that 45 per 100,000 females and 8 per 100,000 men are diagnosed with IC in North America.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.